BMJ Open Systematic scoping review of cluster randomised trials conducted exclusively in low-income and middle-income countries between 2017 and 2022

Cory E Goldstein ⁽¹⁾, ^{1,2} Yacine Marouf ⁽¹⁾, ³ Mira Johri ⁽¹⁾, ^{4,5} Julia F Shaw, ^{1,2} Anand Sergeant, ⁶ Stuart G Nicholls, ^{1,7} Fernando Althabe, ⁸ Rashida A Ferrand, ^{9,10} Rieke van der Graaf, ¹¹ Karla Hemming, ¹² Lawrence Mbuagbaw ⁽¹⁾, ¹³ Shaun Treweek, ¹⁴ Vivian A Welch ⁽¹⁾, ¹⁵ Charles Weijer ⁽¹⁾, ^{6,16,17} Monica Taliaard D 1,2

ABSTRACT

Objective Cluster randomised trials (CRTs) are used for evaluating health-related interventions in low-income and middle-income countries (LMICs) but raise complex ethical issues. To inform the development of future ethics guidance, we aim to characterise CRTs conducted exclusively in LMICs by examining the types of clusters, settings, author affiliations and primary clinical focus and to evaluate adherence to trial registration and ethics reporting requirements over time.

Design A systematic scoping review using the Preferred Reporting Items for Systematic Review and Meta-Analyses Extension for Scoping Reviews.

Data sources We searched MEDLINE between 1 January 2017 and 17 August 2022.

Eligibility criteria for selecting studies We included primary reports of CRTs evaluating health-related interventions, conducted exclusively in LMICs and published in English between 2017 and 2022.

Data extraction and synthesis Data were extracted by one reviewer; a second reviewer verified accuracy by extracting data from 10% of the reports. Results were summarised overall and categorised by country's economic level or publication year.

Results Among 800 identified CRTs, 400 (50.0%) randomised geographical areas and 373 (46.6%) were conducted in Africa. 30 (3.7%) had no authors with an LMIC affiliation, and 246 (30.8%) had neither first nor last author with an LMIC affiliation. The relative frequency of first or last authors holding an LMIC affiliation increases as a country's economic level increases. Most CRTs focused on reducing maternal and neonatal disorders (106, 13.3%). 670 (83.8%) CRTs reported trial registration, 786 (98.2%) reported research ethics committee review and 757 (94.6%) reported consent statements. Among the 757 CRTs, 46 (6.1%) reported a waiver or no consent and, among these, 10 (21.7%) did not provide a rationale. Gatekeepers were identified in 403 (50.4%) CRTs. No meaningful trends were observed in adherence to trial registration or ethics reporting requirements over time. Conclusion Our findings suggest existing inequity in authorship practices. There is high adherence to trial

STRENGTHS AND LIMITATIONS OF THIS STUDY

- \Rightarrow This is the largest review of cluster randomised trials (CRTs) to date and it provides a comprehensive overview of CRTs conducted exclusively in lowincome and middle-income countries.
- \Rightarrow We used the Preferred Reporting Items for Systematic Review and Meta-Analyses Extension for Scoping Reviews to report our methods and results.
- \Rightarrow Stratifying results allowed for comparison across low-income, lower-middle-income and uppermiddle-income country categories.
- \Rightarrow Our search was limited to MEDLINE and the English language and using other databases and languages

 ⇒ Our search was limited to MEDLINE and the English language and using other databases and languages may have identified additional trials but our substantive conclusions would likely not have changed.
 ⇒ Single data extraction was used, although there was high inter-reviewer agreement on a subset of 80 trials used to ensure accuracy and consistency of data extraction.
 registration and ethics reporting requirements, although greater attention to reporting a justification for using a waiver of consent is needed.
 INTRODUCTION
Cluster randomised trials (CRTs) are an important research design for evaluating interventions to address acute and chronic health and public health issues.¹ As opposed to greater attention to report of the section. health and public health issues.¹ As opposed to **B** individually randomised trials that randomly **8** allocate individuals to study interventions, CRTs randomly allocate groups of people or 'clusters' to study interventions. CRT designs are often used when the intervention must be delivered to a group rather than an individual (eg, vector control interventions), when evaluating the direct and indirect effects of interventions such as vaccines, and when there is substantial risk of spillover effects across study

To cite: Goldstein CE, Marouf Y. Johri M. et al. Systematic scoping review of cluster randomised trials conducted exclusively in low-income and middleincome countries between 2017 and 2022. BMJ Open 2024;14:e087724. doi:10.1136/ bmjopen-2024-087724 Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2024-087724).

Received 18 April 2024 Accepted 21 August 2024



C Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BM.J.

For numbered affiliations see end of article.

Correspondence to Dr Cory E Goldstein; cogoldstein@ohri.ca arms resulting in attenuation of intervention effects. These designs might also be particularly useful in lowincome and middle-income counties (LMICs), as they offer logistical and practical advantages over individual randomisation, such as facilitating the fieldwork and intervention delivery across large geographical areas and lowering implementation costs.

Besides the well-documented methodological issues with CRTs, such as their statistical inefficiency and increased risks of bias compared with individually randomised trials,^{3–8} these trials raise complex ethical issues.⁹ The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials-the most comprehensive international ethics guidance document specific to CRTs-proffers 15 recommendations to address ethical issues raised by CRTs (see online supplemental table 1 for Ottawa Statement recommendations).¹⁰

One of the recognised limitations of the Ottawa Statement is the under-representation of LMIC perspectives. The authors 'recommend that subsequent versions include greater LMIC representation,'10 and, since its publication, various efforts have focused on greater collaboration with LMIC representatives to identify issues specific to CRTs in LMICs in need of further guidance.^{1 11–14} To further assist with the identification of unique ethical and methodological issues and inform the forthcoming update of the Ottawa Statement, we conducted a systematic scoping review to describe CRTs in LMICs and create a database of trials that can serve as a rich resource for further in-depth analyses. Specific objectives are: (1) to characterise the types of clusters, settings, author affiliations and primary clinical focus of CRTs in LMICs; (2) to describe adherence to trial registration and ethics reporting requirements-specifically the Ottawa Statement recommendations on research ethics committee review, informed consent and gatekeeping; and (3) to explore variations across income strata and over time.

METHODS

We report our methods and results according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Extension for Scoping Reviews (PRIS-MA-ScR).¹⁵ Our PRISMA-ScR checklist is available in online supplemental table 2.

Search strategy

Our search filter (shown in online supplemental table 3) was adapted from a search used in a previously published systematic review of CRTs evaluating public health interventions in LMICs.¹⁶ The adaptation involved removing public health terms, adding the names of LMICs (as of 16 August 2023), and, for efficiency, superimposing the Cochrane Highly Sensitive Search Strategy for identifying randomised controlled trials.¹⁷ We implemented the search in MEDLINE to identify trials published between 1 January 2017 and 17 August 2022 (the date of the search). We limited our search to MEDLINE, which

≥

similar

The start date because this marks about 5 years since the publication of the *Ottawa Statement*, providing ample opportunity for the dissemination of and adherence to ethics guidance and reporting requirements. **Inclusion and exclusion criteria** Studies were eligible for inclusion if they met the following criteria: (1) published in English language, (2) primary reports of CRTs, (3) evaluated health-related interventions and (4) conducted exclusively in LMICs, classified by the World Bank as low-income, lower-middle-income or upper-middle-income countries.¹⁸ Primary reports were defined as presenting the primary outcomes of the trial. Our strategy for identifying primary reports is reported eas health, healthcare or public health interventions or implementation strategies. Studies were excluded if they met any of the following criteria: (1) no human participants or evaluated a medical education intervention with simulated patients; (2) clusters were households, dyads or families; (3) clusters were individuals with measures on multiple body parts; (4) there was further random or non-random allocation of participants within a trial. Conference abstracts, design papers, editorials, protocols or design papers, pilot and feasibility studies, secondary analyses and process evaluations were also excluded. The full list of inclusion and exclusion criteria is available in the start and and the secondary analyses and process evaluations were also excluded. The full list of inclusion and exclusion criteria is available in the secondary analyses and process evaluations were also excluded. The full list of inclusion and exclusion criteria is available in the secondary analyses and process evaluations were also excluded. The full list of inclusion and exclusion criteria is available in the secondary analyses and process evaluations were also excluded. The full list of inclusion and exclusion criteria is available in the secondary analyses and process evaluations were also excluded. The full list of inclusion and exclusio analyses and process evaluations were also excluded. The ē full list of inclusion and exclusion criteria is available in and online supplemental table 4.

Study selection

data m All identified records were uploaded into Covidence software.²⁰ Title and abstract screening of each record was completed independently by two of four reviewers (AS, CEG, MT and YM) with discrepancies being resolved training, during regular consensus meetings. Six reviewers (AS, CEG, JFS, LQ, MT and YM) proceeded with full-text screening of all potentially eligible studies, with two indeand pendent reviewers screening each record and discrepancies being resolved during regular consensus meetings.

Data extraction

A data extraction form was developed and then pilot tested by 3 reviewers (CEG, MT and YM) using 25 randomly selected eligible records. The final extraction form was uploaded into Covidence software. The form is available in online supplemental table 5. One reviewer 8 (YM) proceeded to extract data from all records, while a second reviewer (CEG) extracted data from 80 records in batches of 10 or 15 records every 2 weeks over 12 weeks to ensure accurate and consistent data extraction. If differences could not be resolved between reviewers, a third reviewer (MT) was considered the final arbitrator.

To address objective 1 (characterise the types of clusters, settings, author affiliations and primary clinical focus of CRTs in LMICs), data were extracted on

type of CRT design (eg, crossover, factorial, parallel arm, stepped wedge), type of cluster (eg, primary care clinics or settings, hospitals or specialised care settings, geographical areas) and country or countries of trial conduct. We reviewed authors' affiliations to determine whether authors of the primary CRT report held LMIC affiliations, and whether first and last authors were affiliated with high-income country institutions, LMIC institutions or both. We recorded detailed information about the primary focus of each CRT using the Institute for Health Metrics and Evaluation's Global Burden of Disease 2019 Cause and Risk Summaries.²¹ We classified the stated primary trial objective in each CRT into one of the three Global Burden of Disease Level I categories; namely, whether the primary objective was (1) to reduce the prevalence or incidence of a disease of health problem, (2) to reduce or prevent health risks or (3) to manage impairments. Trials that could not be classified as (1), (2) or (3) were classified as 'other'. Within each level 1 category, we selected the most relevant level 2 and level 3 subcategories from a drop-down list.

To address objective 2 (examine adherence to trial registration and ethics reporting requirements), data were extracted on whether trials were reported to be registered anywhere in the abstract or full text and, if so, in which trial registries. We extracted whether the study reported research ethics committee approval, exemption or non-submission, and justifications for receiving an exemption from or not submitting a protocol for research ethics committee review. If research ethics committee approval was obtained, we documented the location of the research ethics committee (ie, host country, sponsor county or both). We identified whether a clear statement about participant informed consent was reported. If reported, we extracted from whom consent was obtained (ie, individual-level participants or professional-level participants) or if consent was waived or otherwise not obtained. If consent was reported as waived or otherwise not obtained, any justifications or rationales provided were documented and subsequently categorised. We extracted information on whether a gatekeeper had a reported role and, if so, we documented and post hoc categorised their role in the trial by inductive analysis.

Data analysis

A descriptive analysis was used to summarise results using frequencies and percentages for all categorical variables, and medians and interquartile ranges for continuous variables with skewed distributions. Results were presented overall and stratified by World Bank classifications (ie, low income, lower-middle income, upper-middle income) and publication year (2017-2018, 2019-2020, 2021-2022). For all our analyses, we used R (V.4.3.1).

Patient and public involvement

Patients and members of the public were not involved in the design, conduct, reporting or dissemination plans of this study.

RESULTS

Our search strategy identified 3381 records. After duplicates were removed, 3355 records underwent title and abstract screening. Inter-rater agreement on which **P** studies met the criteria for full-text screening was high (raw percentage agreement 87.4%; kappa statistic 0.83, 95% CI: 0.91 to 1.00) and resulted in 2226 records being excluded. After full-text screening of the remaining 1129 copyright, records, 800 CRTs were included in our review. The study flow diagram is presented in figure 1.

Trial characteristics

Types of CRT designs included parallel arm (716, 89.5%), stepped wedge (45, 5.6%), factorial (30, 3.8%), crossover (8, 1.0%) and parallel adaptive (1, 0.1%). Clusters were most commonly geographical areas (400, 50.0%), primary care clinics or settings (167, 20.9%) and schools or classrooms (110, 13.8%). The three countries in which most CRTs were conducted were India (83, 10.4%), China (78, 9.8%) and Kenya (53, 6.6%). Table 1 presents descriptive characteristics of the 800 CRTs included in our review, online supplemental table 6 presents a full breakdown of 5 CRT conduct by country.

Among 800 CRTs, 30 (3.7%) had no authors affiliated and with an institution based in an LMIC, while 124 (15.5%)were published by authors who were all affiliated with **Q** an institution based in an LMIC. First author affiliations were exclusively within high-income countries in 338 **Ξ** (42.2%) CRTs, exclusively with LMICs in 336 (42.0%) and both high-income country and LMIC affiliations in 126 (15.8%). Last author affiliations were exclusively with high-income countries in 410 (51.2%) CRTs, exclusively with LMICs in 303 (37.9%) and both high-income country and LMIC affiliations in 87 (10.9%). The prevalence of first and last author LMIC affiliation increases as country's economic level increases. In 246 (30.8%) <u>0</u> CRTs, neither first nor last author had an LMIC affiliation. Table 2 provides the descriptive summary of author affiliations.

The most commonly reported primary focus among the 800 CRTs was maternal and neonatal disorders (106, 13.3%), followed by HIV/AIDS and other sexually transmitted infections (91, 11.4%) and malaria and other neglected tropical diseases (88, 11.0%). Figure 2 presents the top 10 primary foci of CRTs in LMICs. Online supplemental table 7 presents a frequency distribution of the primary focus of each CRT, including the Global Burden of Disease level 1, 2 and level 3 categories.²¹

Trial registration and ethics reporting

Table 3 presents information relevant to trial registration and ethics reporting. Among 800 CRTs, 670 (83.8%)



Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.

reported registration in 19 different trial registries. Among the 670 CRTs reporting registration, 642 (95.8%) reported registration in one registry and 28 (4.2%) in two different registries.

A statement about research ethics committee approval was reported in 786 (98.1%) CRTs. Of these, 452 (57.5%) reported review from both host and sponsor country, 315 (40.1%) from host country only, 18 (2.3%) from sponsor country only and 1 (0.1%) reported review from a forprofit ethics committee not associated with either the host or sponsor country.

A statement about consent was reported in 757 (94.6%)CRTs. Among studies with a consent statement, 683 (90.2%) pertained to individual-level participants (eg, patients, students), 56 (7.4%) pertained to professionallevel participants (eg, health providers, teachers), 16 (2.1%) pertained to both individual-level and professional-level participants and 2 (0.3%) were unclear.

Informed consent was reported as being obtained for all aspects of the trial in 711 (93.9%) CRTs, obtained for only some aspects of the trial (eg, data collection procedures) in 20 (2.7%) and not obtained or waived for all aspects of the trial in 25 (3.3%). One (0.1%) CRT reported obtaining written informed consent from participants enrolled at three study sites, while a waiver of consent was granted at 30 study sites.

For CRTs in which consent was not obtained or waived for some or all aspects of the trial, 36 (78.3%) provided

a rationale. Rationales included the use of deidentified routinely collected data, administrative data or registry routinely collected data, administrative data or registry data (23, 63.9%), the research involves a standard of a care or usual care intervention (6, 17.7%), consent was obtained from gatekeepers (4, 11.1%), the research involves a cluster-level intervention (3, 8.3%) and other (14, 38.9%).

training A gatekeeper's role was identified in 403 (50.4%) CRTs. Identified gatekeeper roles included: assisting with study implementation or intervention development; facilitating or involved in consultations, engagement activities or public events; identifying eligible clusters or participants; providing or withholding access to data or study intervention(s); providing or withholding permission for study conduct or to approach cluster members; technologies providing proxy consent on behalf of cluster members; and reviewing or approving study protocols.

No meaningful changes over time were observed with respect to reporting of trial registration or consent.

DISCUSSION

Summary of key findings

This systematic scoping review characterises the types of clusters, settings, author affiliations and primary clinical focus of CRTs in LMICs. Geographical areas were the most common units of randomisation. We found that most CRTs were conducted in India, China and Kenya. Almost

and

Protected by copyright, including for uses related to text

	Frequency (%)					
	Exclusively low-income countries	Exclusively lower-middle- income countries	Exclusively upper-middle- income countries	Total*		
	N=183	N=397	N=210	N=800		
Publication year						
2017	34 (18.6)	54 (13.6)	33 (15.7)	121 (15.1)		
2018	26 (14.2)	48 (12.1)	32 (15.2)	108 (13.5)		
2019	33 (18.0)	77 (19.4)	34 (16.2)	148 (18.5)		
2020	33 (18.0)	74 (18.6)	42 (20.0)	151 (19.0)		
2021	47 (25.7)	91 (22.9)	38 (18.1)	177 (22.1)		
2022	10 (5.46)	53 (13.3)	31 (14.8)	95 (11.8)		
Trial design						
Parallel arm	165 (90.2)	353 (88.9)	189 (90.0)	716 (89.5)		
Stepped wedge	10 (5.46)	21 (5.3)	12 (5.7)	45 (5.6)		
Factorial	7 (3.8)	17 (4.3)	7 (3.3)	30 (3.8)		
Crossover	0 (0.0)	6 (1.5)	2 (1.0)	8 (1.0)		
Parallel adaptive	1 (0.5)	0 (0.0)	0 (0.0)	1 (0.1)		
Jnit of randomisation						
Geographical areas	102 (55.7)	228 (57.4)	64 (30.5)	400 (50.0)		
Primary care clinics/ settings	49 (26.8)	72 (18.1)	43 (20.5)	167 (20.9)		
Schools/classrooms	8 (4.4)	54 (13.6)	48 (22.9)	110 (13.8		
Hospitals or specialised care settings	4 (2.2)	19 (4.8)	26 (12.4)	50 (6.3)		
Professionals	4 (2.2)	1 (0.3)	9 (4.3)	14 (1.8)		
Workplaces	0 (0.0)	3 (0.8)	8 (3.8)	11 (1.4)		
Childcare institutions	2 (1.1)	1 (0.3)	5 (2.4)	8 (1.0)		
Residential complexes	1 (0.5)	4 (1.0)	1 (0.5)	6 (0.8)		
Mixed units of randomisation	2 (1.1)	5 (1.3)	1 (0.5)	8 (1.0)		
Other†	11 (6.0)	10 (2.5)	5 (2.4)	26 (3.25)		
NHO region of trial conduc	t					
Africa	181 (98.9)	155 (39.0)	37 (17.6)	373 (46.6		
South-East Asia	0 (0.0)	160 (40.3)	15 (7.1)	175 (21.9)		
Western Pacific	0 (0.0)	29 (7.3)	88 (41.9)	117 (14.6		
Americas	0 (0.0)	2 (0.5)	63 (30.0)	65 (8.1)		
Eastern Mediterranean	2 (1.1)	50 (12.6)	1 (0.5)	53 (6.6)		
Europe	0 (0.0)	0 (0.0)	5 (2.4)	5 (0.6)		
Multiregional	0 (0.0)	1 (0.3)	1 (0.5)	12 (1.5)		

*N=10 were multinational cluster randomised trials conducted in mixed economies, for example, both low-income and lower-middle-income countries.

†Other units of randomisation include: days of the week or time of clinic presentation; caregivers and their children; individual with an illness and their close contacts; microfinance loan groups; nursing homes or long-term care facilities; orphanages; pharmacies or dispensaries; places of worship; prisons; recreational community clubs; and support groups.

all CRTs included at least one author with an LMIC affiliation, but a substantial minority had neither first nor last author with an LMIC affiliation. We also found that the relative frequency of all authors having exclusively

LMIC affiliations increases as a country's economic level increases and that the prevalence of the first or last author having exclusively LMIC affiliations increases as a country's economic level increases. The most common

		6	BMJ
			Opei
			n: fir
ddle-	Total*		st pu
	N=800		ıblis
			hed
	770 (96.	3)	as
	30 (3.7)		10.1 Pro
	124 (15.	5)	136/I
	676 (84.	5)	bmjo ted l
			oper oy c
	338 (42.2	2)	1-20 סpyו
	336 (42.	C)	24-0 right
	126 (15.	5)	877:
	410 (51 :	2)	24 o clud
	303 (37.9	9)	n 17 ing 1
	87 (10.9)		'Sel
			pten Ens Ises
	554 (69.	2)	nber seigi s rela
	246 (30.)	8)	202 nem ated
lower-r	niddle-incc	me	24. Dow ent Sup to text
Cs rep ce to leal. N ethi	ort trial ethics re Nearly all ics comm	regis- ecom- CRTs nittee	led from http://bmjopen.bmj.com/ on June 7, ź ιr (ABES) data mining, Al training, and similar technoloς
100 ne cou se and	untries.* d Risk	120	:025 at Agence Bibliographiqu ies.
			Je d
1136/bn	njopen-2024-	087724	e

Figure 2 Top 10 primary clinical focus of n=800 cluster randomised trials in low-income and middle-income countries.* Categories taken from the Institute for Health Metrics and Evaluation's Global Burden of Disease 2019 Cause and Risk Summaries.

40

60

Number of cluster randomized trials

20

	Frequency (%)					
	Exclusively low- income countries	Exclusively lower-middle- income countries	Exclusively upper-middle- income countries	Total*		
	N=183	N=397	N=210	N=800		
Was at least one author aff	iliated with an LMIC?					
Yes	175 (95.6)	379 (95.5)	206 (98.1)	770 (96.3)		
No	8 (4.4)	18 (4.5)	4 (1.9)	30 (3.7)		
Were all authors affiliated with an LMIC?						
Yes	13 (7.1)	55 (13.9)	56 (26.7)	124 (15.5)		
No	170 (89.9)	342 (86.1)	154 (73.3)	676 (84.5)		
What was the first author's affiliation?						
Exclusively HIC	95 (51.9)	185 (46.6)	51 (24.3)	338 (42.2)		
Exclusively LMIC	52 (28.4)	147 (37.0)	134 (63.8)	336 (42.0)		
Joint HIC and LMIC	36 (19.7)	65 (16.4)	25 (11.9)	126 (15.8)		
What was the last author's affiliation?						
Exclusively HIC	109 (59.6)	226 (56.9)	66 (31.4)	410 (51.2)		
Exclusively LMIC	54 (29.5)	129 (32.5)	120 (57.1)	303 (37.9)		
Joint HIC and LMIC	20 (10.9)	42 (10.6)	24 (11.4)	87 (10.9)		
Was either the first or last author affiliated with an LMIC?						
Yes	119 (65.0)	255 (64.2)	176 (83.8)	554 (69.2)		
No	64 (35.0)	142 (35.8)	34 (16.2)	246 (30.8)		
*N=10 were multinational cluster randomised trials conducted in mixed economies, for example, both low-income and lower-middle-income						

Table 2 Overview of author affiliations among n=800 cluster randomised trials included in the review

countries.

HIC, high-income country; LMIC, low-income and middle-income country.

primary clinical focus of CRTs in LMICs were to reduce the prevalence or incidence of maternal and neonatal disorders, HIV/AIDS and other sexually transmitted diseases and malaria or other neglected tropical diseases.

Maternal or neonatal disorders

Mental disorders Dietary risks

0

Cardiovascular diseases Nutritional deficiencies

HIV/AIDS and sexually transmitted infections Neglected tropical diseases and malaria Risk of child and maternal malnutrition Unsafe water, sanitation, and handwashing

Respiratory infections and tuberculosis

We found that most CRTs in LMIC tration. We also found that adheren mendations was high, although not id report a statement about research



80

Was trial registration reported?†

Number of registries reported

Was a statement about research Yes, reported REC approval Yes, reported REC exemption

Where was the REC located? Both host and sponsor country

Was a statement about consent

To whom did the statement about Individual-level participants

Was informed consent obtained

Was a rationale for not obtaining waiver of consent provided?

all aspects of the trial?

the waiver of consent?**

2017-2018N=229As trial registration reported?†Yes190 (83.0)No39 (17.0)umber of registries reported181 (95.3)Two9 (4.7)As a statement about research ethics committee review reported?Yes, reported REC approval222 (96.9)Yes, reported REC exemption0 (0.0)Yes, reported net submitted for REC review0 (0.0)No7 (3.1)/here was the REC located?0 (0.0)Sponsor country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)/as a statement about consent provided?14 (6.1)Yes215 (93.9)No14 (6.1)Owhom did the statement about consent pertain?16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or l aspects of the trial?20 (94.0)Yes, consent was obtained for some aspects of trial20 (94.0)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	2019–2020 N=299 254 (84.9) 45 (15.1) 240 (94.5) 14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	2021–2022 N=272 226 (83.1) 46 (16.9) 220 (97.3) 6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	Total* N=800 670 (83.8) 130 (16.2) N=670 641 (95.6) 29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
N=229As trial registration reported?†Yes190 (83.0)No39 (17.0)umber of registries reported181 (95.3)Two9 (4.7)As a statement about research ethics committee =view reported?Yes, reported REC approval222 (96.9)Yes, reported REC exemption0 (0.0)No7 (3.1)Yher was the REC located?136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)No146 (61.3)Yes a statement about consent provided?146 (1)Yes15 (93.9)No14 (61.1)Ohm did the statement about consent previde?100.0Yes15 (93.9)No14 (61.1)Orthodial-level participants16 (7.4)Professional-level participants20 (9.0)Andreak20 (9.0)Andreak20 (9.0)Andreak20 (9.0)Aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (9.0)Yes, consent was obtained for some aspects of the tria?20 (0.0)	N=299 254 (84.9) 45 (15.1) 240 (94.5) 14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	N=272 226 (83.1) 46 (16.9) 220 (97.3) 6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	N=800 670 (83.8) 130 (16.2) N=670 641 (95.6) 29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Yes 190 (83.0) No 39 (17.0) umber of registries reported 181 (95.3) Two 9 (4.7) As a statement about research ethics committee review reported? Yes, reported REC approval 222 (96.9) Yes, reported REC exemption 0 (0.0) Yes, reported REC located? 0 (0.0) No 0 (0.0) Yes, reported not submitted for REC review 0 (0.0) No 70 (35.6) Sponsor country only 79 (35.6) Sponsor country only 7 (3.2) Yes No 136 (61.3) Yes No 136 (61.3) Yes Professional deponsor country 1 0 (0.0) Yes Sponsor country only 7 (3.2) Yes No 14 (6.1) Yes Owhom did the statement about consent provided? Yes Yes 215 (93.9) Yes No 14 (6.1) Yes Othorn did the statement about consent protain Yes Professional-level participants 197 (91.6) Both individual-level participants 10 (0.0) Yes, consent was obtained or not for some arrow of aspects of th	254 (84.9) 45 (15.1) 240 (94.5) 14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	226 (83.1) 46 (16.9) 220 (97.3) 6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	670 (83.8) 130 (16.2) N=670 641 (95.6) 29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Yes190 (83.0)No39 (17.0)umber of registries reported181 (95.3)Two9 (4.7)Vas a statement about research ethics committee	254 (84.9) 45 (15.1) 240 (94.5) 14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	226 (83.1) 46 (16.9) 220 (97.3) 6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	670 (83.8) 130 (16.2) N=670 641 (95.6) 29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
No39 (17.0)umber of registries reported181 (95.3)Two9 (4.7)//as a statement about research ethics committee review reported?Yes, reported REC approval222 (96.9)Yes, reported REC exemption0 (0.0)Yes, reported not submitted for REC review0 (0.0)No7 (3.1)//here was the REC located?79 (35.6)Sponsor country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)//as a statement about consent provided?136 (61.3)Yes215 (93.9)No14 (6.1)Owhom did the statement about consent pertain?107 (91.6)Porfessional-level participants197 (91.6)Both individual-level and professional-level participants100.0)Ves, consent was obtained for all aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial?202 (94.0)Yes, consent was obtained for some aspects of the trial?202 (94.0)Yes, consent was obtained for some aspects of the trial?202 (94.0)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	45 (15.1) 240 (94.5) 14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	46 (16.9) 220 (97.3) 6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	130 (16.2) N=670 641 (95.6) 29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
umber of registries reported 181 (95.3) Two 9 (4.7) 'as a statement about research ethics committee review reported? Yes, reported REC approval 222 (96.9) Yes, reported REC exemption 0 (0.0) No 7 (3.1) Yhere was the REC located? 136 (61.3) No Both host and sponsor country 136 (61.3) No Yes reported nor submisted for REC review 0 (0.0) No Yes reported not submisted for REC review 0 (0.0) No No 7 (3.1) Yes Horts country only 79 (35.6) Sponsor country only 7 (3.2) Neither host nor sponsor country‡ 0 (0.0) Yes Yes 215 (93.9) No 14 (6.1) Whom did the statement about consent pertain? Yes Yes Yes 197 (91.6) Spoth individual-level participants 197 (91.6) Both individual-level participants 2 (0.9) Yes Yes Unclear§ 0 (0.0) Yes Yes Yes Yes, consent was obtained for all aspects of the trial? Yes, conse	240 (94.5) 14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	220 (97.3) 6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	N=670 641 (95.6) 29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
One181 (95.3)Two9 (4.7)As a statement about research ethics committee review reported?Yes, reported REC approval222 (96.9)Yes, reported REC exemption0 (0.0)No7 (3.1)Phere was the REC located?7 (3.1)Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)/as a statement about consent provided?215 (93.9)Yes215 (93.9)No14 (6.1)owhom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for some aspects of the trial7 (3.3)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	240 (94.5) 14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	220 (97.3) 6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	641 (95.6) 29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Two9 (4.7)Two9 (4.7)As a statement about research ethics committee view reported?Yes, reported REC approval222 (96.9)Yes, reported REC exemption0 (0.0)No7 (3.1)Nere was the REC located?7 (3.2)Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)as a statement about consent provided?14 (6.1)Yes215 (93.9)No14 (6.1)owhom did the statement about consent pertain?197 (91.6)Porfessional-level participants197 (91.6)Both individual-level and professional-level16 (7.4)participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	14 (5.5) 295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	6 (2.7) 269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	29 (4.4) 786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
as a statement about research ethics committee review reported?Yes, reported REC approval222 (96.9)Yes, reported REC exemption0 (0.0)No7 (3.1)here was the REC located?0 (0.0)Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)as a statement about consent provided?0 (0.0)Yes215 (93.9)No14 (6.1)owhom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial?202 (94.0)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	295 (98.7) 0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Yes, reported REC approval222 (96.9)Yes, reported REC exemption0 (0.0)Yes, reported not submitted for REC review0 (0.0)No7 (3.1)here was the REC located?136 (61.3)Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)as a statement about consent provided?14 (6.1)Yes215 (93.9)No14 (6.1)o whom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial?7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Yes, consent was obtained for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	295 (98.7) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	269 (98.9) 0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	786 (98.2) 0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Yes, reported REC exemption0 (0.0)Yes, reported not submitted for REC review0 (0.0)No7 (3.1)There was the REC located?136 (61.3)Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)as a statement about consent provided?14 (6.1)Yes215 (93.9)No14 (6.1)o whom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial7 (3.3)No, a waiver of consent was granted or no consent obtained6 (2.8)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	0 (0.0) 0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	0 (0.0) 0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	0 (0.0) 0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Yes, reported not submitted for REC review0 (0.0)No7 (3.1)Nere was the REC located?Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)Yes215 (93.9)No14 (6.1)o whom did the statement about consent pertain?Individual-level participants197 (91.6)Both individual-level participants2 (0.9)Unclear§0 (0.0)'as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial7 (3.3)Other¶0 (0.0)	0 (0.0) 4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	0 (0.0) 3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	0 (0.0) 14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
No7 (3.1)There was the REC located?136 (61.3)Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)das a statement about consent provided?14 (6.1)Yes215 (93.9)No14 (6.1)o whom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for some aspects of the trial202 (94.0)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)as a rationale for not obtaining consent or a0 (0.0)	4 (1.3) 175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	3 (1.1) 142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	14 (1.8) N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Phere was the REC located?Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)das a statement about consent provided?215 (93.9)No14 (6.1)whom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as apects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Other¶0 (0.0)as a rationale for not obtaining consent or a0 (0.0)	175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	N=786 452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Both host and sponsor country136 (61.3)Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)'as a statement about consent provided?215 (93.9)Yes215 (93.9)No14 (6.1)whom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)'as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)as a rationale for not obtaining consent or a0 (0.0)	175 (59.3) 113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	142 (52.8) 122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	452 (57.5) 315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Host country only79 (35.6)Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)As a statement about consent provided?215 (93.9)Yes215 (93.9)No14 (6.1)whom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)'as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)Yes, consent was obtained for some aspects of the trial6 (2.8)'Yes, consent was obtained for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of a for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of a for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of a for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of a for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of a for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of a for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of the trial0 (0.0)Yes, consent was obtained for some aspects of the trial0	113 (38.3) 6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	122 (45.4) 5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	315 (40.1) 18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Sponsor country only7 (3.2)Neither host nor sponsor country‡0 (0.0)As a statement about consent provided?215 (93.9)Yes215 (93.9)No14 (6.1)whom did the statement about consent pertain?197 (91.6)Both individual-level participants197 (91.6)Both individual-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial7 (3.3)Other¶0 (0.0)as a rationale for not obtaining consent or a0 (0.0)	6 (2.0) 1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	5 (1.9) 0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	18 (2.3) 1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Neither host nor sponsor country‡0 (0.0)'as a statement about consent provided?215 (93.9)Yes215 (93.9)No14 (6.1)o whom did the statement about consent pertain?197 (91.6)Individual-level participants197 (91.6)Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or l aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	1 (0.3) 288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	0 (0.0) 254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	1 (0.1) 757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Yes215 (93.9)No14 (6.1)whom did the statement about consent pertain?Individual-level participants197 (91.6)Both individual-level and professional-level16 (7.4)participants2 (0.9)Unclear§0 (0.0)as pects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Yes215 (93.9)No14 (6.1)No14 (6.1)whom did the statement about consent pertain?Individual-level participants197 (91.6)Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or l aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	288 (96.3) 11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	254 (93.4) 18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	757 (94.6) 43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
No14 (6.1)whom did the statement about consent pertain?197 (91.6)Individual-level participants197 (91.6)Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	11 (3.7) 261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	18 (6.6) 225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	43 (5.4) N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
whom did the statement about consent pertain?Individual-level participants197 (91.6)Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or a spects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	N=757 683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Individual-level participants197 (91.6)Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or l aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)as a rationale for not obtaining consent or a0 (0.0)	261 (90.6) 18 (6.2) 7 (2.4) 2 (0.7)	225 (88.6) 22 (8.7) 7 (2.8) 0 (0.0)	683 (90.2) 56 (7.4) 16 (2.1) 2 (0.3)
Both individual-level and professional-level participants16 (7.4)Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or l aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)	18 (6.2) 7 (2.4) 2 (0.7)	22 (8.7) 7 (2.8) 0 (0.0)	56 (7.4) 16 (2.1) 2 (0.3)
Professional-level participants2 (0.9)Unclear§0 (0.0)as informed consent obtained or not for some or aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)as a rationale for not obtaining consent or a0 (0.0)	7 (2.4) 2 (0.7)	7 (2.8) 0 (0.0)	16 (2.1) 2 (0.3)
Unclear§0 (0.0)as informed consent obtained or not for some or I aspects of the trial?202 (94.0)Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)as a rationale for not obtaining consent or a	2 (0.7)	0 (0.0)	2 (0.3)
'as informed consent obtained or not for some or l aspects of the trial? Yes, consent was obtained for all aspects of the trial No, a waiver of consent was granted or no consent obtained Yes, consent was obtained for some aspects of the trial Other¶ 0 (0.0) 'as a rationale for not obtaining consent or a			()
Yes, consent was obtained for all aspects of the trial202 (94.0)No, a waiver of consent was granted or no consent obtained7 (3.3)Yes, consent was obtained for some aspects of the trial6 (2.8)Other¶0 (0.0)as a rationale for not obtaining consent or a			N=757
No, a waiver of consent was granted or no 7 (3.3) consent obtained 7 (3.3) Yes, consent was obtained for some aspects of the trial 6 (2.8) Other¶ 0 (0.0) as a rationale for not obtaining consent or a	268 (93.1)	241 (94.9)	711 (93.9)
Yes, consent was obtained for some aspects of the trial 6 (2.8) Other¶ 0 (0.0) Vas a rationale for not obtaining consent or a 0 (0.0)	13 (4.5)	5 (2.0)	25 (3.3)
Other¶ 0 (0.0) as a rationale for not obtaining consent or a	6 (2.1)	8 (3.1)	20 (2.7)
as a rationale for not obtaining consent or a	1 (0.3)	0 (0.0)	1 (0.1)
aiver of consent provided?			N=46
Yes 10 (76.9	15 (75.0)	11 (84.6)	36 (78.3)
No 3 (23.1)	5 (25.0)	2 (15.4)	10 (21.7)
hat was the rationale for not obtaining consent or e waiver of consent?**			N=36
Trial only uses deidentified, routinely collected 5 (50.0) data	8 (53.3)	4 (36.4)	17 (47.2)
Trial only uses anonymised data (eg, administrative databases, registries)2 (20.0)	4 (26.7)	5 (45.5)	11 (30.6)

Table 3	Adherence to trial registration and ethics reporting requirements in n=800 cluster randomised trials included in th
review	

Table 3 Continued

	Eroquepov (0/)			
	Frequency (%)			
Trial involves usual care or standard of care treatments	2 (20.0)	3 (20.0)	1 (9.1)	6 (16.7)
Trial is evaluating a cluster-level intervention	0 (0.0)	2 (13.3)	1 (9.1)	3 (8.3)
Trial poses no more than minimal risk	1 (10.0)	0 (0.0)	1 (9.1)	2 (5.6)
Trial would be infeasible with informed consent	0 (0.0)	1 (6.67)	1 (9.1)	2 (5.6)
Trial has important social value	0 (0.0)	1 (6.67)	0 (0.0)	1 (2.8)
Other ^{††}	3 (30.0)	6 (40.0)	3 (27.3)	12 (33.3)
Was a gatekeeper role reported in the trial?				
Yes	127 (55.5)	150 (50.2)	126 (46.3)	403 (50.4)
No	92 (40.2)	124 (41.5)	134 (49.3)	350 (43.7)
Unclear‡‡	10 (4.4)	25 (8.4)	12 (4.4)	47 (5.9)

*N=10 were multinational cluster randomised trials conducted in mixed economies, for example, both low-income and lower-middle-income countries.

†The three most common trial registries were ClinicalTrials.gov (NCT), International Standard Randomised Controlled Trial Number and Pan African Clinical Trial Registry.

‡For-profit research ethics committee not associated with the host or sponsor countries.

§Unclear statements of consent referred to consent without specifying from whom consent was obtained.

¶A waiver of consent was granted for all aspects of the trial at 30 sites, while written informed consent was required for all aspects of the trial at three sites.

**Multiple rationales for not obtaining consent or waiving consent are possible; frequencies do not add up to 100%.

††Consent was obtained from a gatekeeper; consent from parents/legal guardian is not required when obtained from minors; consent would preclude large numbers of eligible participants; consent would introduce bias; health providers have a duty to participate in research; trial is evaluating a quality improvement intervention; trial is observing public behaviour; trial does not involve a biomedical intervention; and trial uses cluster randomisation.

^{‡‡}Unclear statements include, for example, 'clinics agreeing to participate'. No gatekeeper is clearly identified in such statements, but a gatekeeper role is clearly identified.

REC, research ethics committee.

review and approval. Almost all CRTs reported a statement about consent and, when reported, it was almost always clear from whom consent was obtained. However, when consent was reported as not obtained or waived, a substantial minority of CRTs did not report a justification. Many of the provided justifications were not consistent with or explicitly rejected by the *Ottawa Statement* recommendations.

Implications of key findings

One of the most common justifications for adopting a CRT design over an individually randomised design is to avoid contamination between study arms.²² When geographical areas are selected as the unit of randomisation—which we found to be typical of CRTs in LMICs—there is often a substantial risk of spillover effects caused by migration of individuals between clusters that can undermine the scientific validity of a CRT. Future in-depth analyses should explore any efforts to avoid or mitigate contamination between geographical clusters in these trials.

First and last authorship positions are considered prestigious and are often used by funding agencies reviewing grants and by institutions evaluating applications for promotion. Yet, researchers affiliated with LMIC institutions are often 'stuck in the middle when it comes to global health authorship resulting from international

 1 (6.67)
 0 (0.0)
 1 (2.8)

 6 (40.0)
 3 (27.3)
 12 (33.3)

 150 (50.2)
 126 (46.3)
 403 (50.4)

 124 (41.5)
 134 (49.3)
 350 (43.7)

 25 (8.4)
 12 (4.4)
 47 (5.9)

 conomies, for example, both low-income and lower-middle-income
 ernational Standard Randomised Controlled Trial Number and Pan

 onsor countries.
 m whom consent was obtained.
 hile written informed consent was required for all aspects of the trial

 sible; frequencies do not add up to 100%.
 guardian is not required when obtained from minors; consent would bias; health providers have a duty to participate in research; trial is haviour; trial does not involve a biomedical intervention; and trial

 e'. No gatekeeper is clearly identified in such statements, but a

 partnerships'.²³ Our findings suggest that this holds true for many CRTs in LMICs. To take steps towards rectifying inequities in authorship, researchers affiliated with high-income-country institutions should, at the very least, create more opportunities for local LMIC-affiliated collaborators to contribute to CRTs in ways that lead to first and last authorship.²⁴

The primary focus of CRTs in LMICs are oriented Ы towards communicable, maternal, neonatal and nutritional diseases, which corresponds to the focus of the global donor community during the Millennium Development Goals period (2000-2015).²⁵ Since we did not explore this issue in our data, we can only speculate that many of these studies are donor driven. Priorities should evolve, if they have not started to do so already, to address the 'rapid rise in non-communicable diseases and disabilities' that currently account for much of the burden of disease worldwide (with the exception of countries early in the epidemiological transition).²⁶ The focus of future CRTs in LMICs should correspond to local burden of disease that are of national importance in the Sustainable Development Goals period (2016–2030).²⁷

Finally, almost all CRTs in LMICs were compliant with trial registration and ethics reporting recommendations. Yet, there is room for improved reporting of justifications for not obtaining consent or using a waiver of consent. A probable reason for poor reporting is that it is not required by most journals or trial reporting guidelines. However, the Consolidated Standards of Reporting Trials extension for stepped-wedge CRTs states, 'When a waiver or modification of consent has been granted by a research ethics committee, it should be reported and a justification given. It should be clear whose consent was waived and whether the waiver pertains to study participation, data collection or both'.²⁸ Other reporting guidelines ought to be updated to improve reporting of consent practices in CRTs.

Comparison with other studies

This is the first study to describe the characteristics of CRTs conducted exclusively in LMICs. Two previous studies have also examined the characteristics of CRTs and ethics reporting, although none is specific to LMICs: a review of 300 primary CRT reports published between 2000 and 2008²⁹; and a review of 173 articles reporting primary or secondary analysis of CRTs published in 2008.³⁰ These reviews found that 15%–25% of CRTs are conducted in LMICs. Consistent with our findings, these reviews also found that geographical areas are commonly the units of randomization in CRTs; yet, CRTs in LMICs are more likely to randomise geographical areas (50%) than CRTs in general (15%).²⁹

In terms of trial registration requirements, Odutayo et al's cross-sectional study of 1122 primary reports of randomised controlled trials published in December 2012 found that only 593 (52.9%) reported trial registration.³¹ Among the 1122 trials, 31 (2.8%) were CRTs and, of these, 17 (54.8%) reported trial registration. Our review suggests that CRTs in LMICs are more likely to report trial registration in the primary report than randomised controlled trials and CRTs in general or that a substantial improvement in trial registration has occurred over the last 10 years.

Finally, in terms of ethics reporting, the two aforementioned reviews found that 73%-90% of CRTs include a statement about research ethics committee approval and 69%-83% include a statement about informed consent.²⁹³⁰ Compared with these earlier reviews, our review found a higher percentage of reporting research ethics committee approval (98.2%) and informed consent (94.6%), which suggests that adherence to ethics reporting requirements may be higher in CRTs conducted exclusively in LMICs or that an improvement has occurred over time.

Strengths and limitations

Our study is the largest review of CRTs conducted to date and provides a comprehensive overview of CRTs in LMICs. It has also created a large database of CRTs that can serve as a rich recourse for further in-depth analysis. Our study has some limitations. First, by excluding CRTs conducted in high-income countries from the search and only included trials conducted exclusively in LMICs, we cannot compare the two sets of trials. This limits our

ability to accurately identify ethical issues that are unique to trials conducted in LMICs. However, stratifying results allowed for some comparison between LMIC categories. Second, our literature search was limited to MEDLINE and the English language; using other databases and languages may have identified additional trials. However, since our study objectives relate to a general characterisation of CRTs conducted in LMICs and a description of their adherence to trial registration and ethics reporting requirements, capturing a large, representative sample τ of such trials was considered adequate. Searching other databases and including non-English primary reports of CRTs would have been unlikely to yield substantively different conclusions. Third, single data extraction was used since the scope of this review would render dupli-8 cate review unmanageable. To limit misclassification, the primary extractor underwent multiple rounds of training grior to commencing data extraction and the extraction **,** form provided clear guidance and examples. There was ncluding also high inter-reviewer agreement on the subset of 80 trials that were used to ensure accuracy and consistency of data extraction.

CONCLUSION

In this review, which is part of a larger project to update the Ottawa Statement, we compiled a large database of 800 CRTs conducted exclusively in LMICs, characterised the ē types of clusters, settings, author affiliations and primary clinical focus of these trials and evaluated their adherence to trial registration and ethics reporting requirements. Our findings suggest existing inequity in authorship pracđ tices. We also found high adherence to trial registration \exists and ethics reporting requirements, although greater attention to reporting a justification for using a waiver of consent is needed. Future secondary analyses will examine training, specific ethical and methodological issues in more detail to ensure that the updated Ottawa Statement recommendations are applicable to all CRTs irrespective of location, while also providing recommendations to address unique issues raised by CRTs in LMICs.

Author affiliations

- ¹Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- ²School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
- ³Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada ⁴Centre de recherche du CHUM, Montreal, Quebec, Canada
- ⁵Département de gestion, d'évaluation, et de politique de santé, École de santé publique de l'Université de Montréal, Montreal, Quebec, Canada
- ⁶Department of Medicine, Western University, London, Ontario, Canada

⁷Office for Patient Engagement in Research Activity, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

- ⁸Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina
- ⁹Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
- ¹⁰Biomedical Research and Training Institute, Harare, Zimbabwe

¹¹Department of Bioethics and Health Humanities, University Medical Centre Utrecht, Utrecht, The Netherlands

5

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

¹²Institute of Applied Healthcare Research, University of Birmingham, Birmingham, UK

- ¹³Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
- ¹⁴Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, UK
- ¹⁵Bruyère Research Institute, Ottawa, Ontario, Canada
- ¹⁶Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada
- ¹⁷Department of Philosophy, Western University, London, Ontario, Canada
- X Charles Weijer @charlesweijer

Acknowledgements The authors would like to thank Laura Quinn (LQ) for assisting with full-text screening and Spencer Phillip Hey (SPH) for assisting with ClincalTrials.gov data extraction and linkage.

Contributors CEG, CW and MT conceived of the project and developed the extraction form with MJ, SGN and YM. Record screening was completed by AS, CEG, JFS, LQ, MT and YM. YM completed data extraction and the statistical analysis with assistance from CEG and MT. CEG wrote the first draft of the manuscript with input from CW, JFS, MT and YM and was responsible for revisions of subsequent drafts. AS, CW, FA, JFS, KH, LM, MJ, MT, RAF, RvdG, SGN, ST, VAW and YM provided feedback on subsequent drafts, had full access to all data and approved the decision to submit for publication. CEG is the guarantor of the manuscript.

Funding This work was supported by a Canadian Institutes of Health Research (CIHR) project grant (PJT-479757). CEG is supported by a CIHR Fellowship Award. These funding sources had no role in the study design, data collection, data analysis, data interpretation, writing of the report or decision to publish.

Competing interests CW receives consulting income from Cardialen and Eli Lilly & Company. Other authors declare no competing interests.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Cory E Goldstein http://orcid.org/0000-0002-0229-5039 Yacine Marouf http://orcid.org/0009-0005-4852-4860 Mira Johri http://orcid.org/0000-0001-5642-787X Lawrence Mbuagbaw http://orcid.org/0000-0001-5855-5461 Vivian A Welch http://orcid.org/0000-0002-5238-7097 Charles Weijer http://orcid.org/0000-0002-5510-1074 Monica Taljaard http://orcid.org/0000-0002-3978-8961

REFERENCES

- Sullivan SG, Wu Z, et al. Community-based intervention trials in lowand middle-income countries. In: Detels R, ed. Oxford textbook of global public health. 6th edn. Oxford, 2015.
- 2 Dron L, Taljaard M, Cheung YB, et al. The role and challenges of cluster randomised trials for global health. Lancet Glob Health 2021;9:e701–10.

- 3 Torgerson DJ. Contamination in trials: is cluster randomisation the answer? BMJ 2001;322:355–7.
- 4 Campbell MK, Grimshaw JM, Elbourne DR. Intracluster correlation coefficients in cluster randomized trials: empirical insights into how should they be reported. *BMC Med Res Methodol* 2004;4:9.
- 5 Hahn S, Puffer S, Torgerson DJ, et al. Methodological bias in cluster randomised trials. *BMC Med Res Methodol* 2005;5:10.
- 6 Eldridge S, Kerry S, Torgerson DJ. Bias in identifying and recruiting participants in cluster randomised trials: what can be done? *BMJ* 2009;339:bmj.b4006.
- 7 Hemming K, Taljaard M. Reflection on modern methods: when is a stepped-wedge cluster randomized trial a good study design choice? *Int J Epidemiol* 2020;49:1043–52.
- 8 Easter C, Thompson JA, Eldridge S, et al. Cluster randomized trials of individual-level interventions were at high risk of bias. J Clin Epidemiol 2021;138:49–59.
- 9 Weijer C, Grimshaw JM, Taljaard M, *et al.* Ethical issues posed by cluster randomized trials in health research. *Trials* 2011;12:100.
- 10 Weijer C, Grimshaw JM, Eccles MP, *et al.* The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials. *PLoS Med* 2012;9:e1001346.
- 11 Joag K, Ambrosio G, Kestler E, et al. Ethical issues in the design and conduct of stepped-wedge cluster randomized trials in low-resource settings. *Trials* 2019;20:703.
- 12 Mtande TK, Weijer C, Hosseinipour MC, *et al.* Ethical issues raised by cluster randomised trials conducted in low-resource settings: identifying gaps in the *Ottawa Statement* through an analysis of the PURE Malawi trial. *J Med Ethics* 2019;45:388–93.
- 13 Howie A, Taljaard M, Moon PM, et al. Addressing the disconnect between trial intention and design. Lancet Glob Health 2021;9:e577–8.
- 14 Park JJH, Grais RF, Taljaard M, et al. Urgently seeking efficiency and sustainability of clinical trials in global health. Lancet Glob Health 2021;9:e681–90.
- 15 Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and Explanation. Ann Intern Med 2018;169:467–73.
- 16 Pérez MC, Minoyan N, Ridde V, et al. Comparison of registered and published intervention fidelity assessment in cluster randomised trials of public health interventions in low- and middle-income countries: systematic review. *Trials* 2018;19:410.
- 17 Lefebvre C, Glanville J, Briscoe S, et al. Technical supplement to chapter 4: searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, eds. Cochrane handbook for systematic reviews of interventions. 2019. Available: https://training.cochrane. org/handbook
- 18 The World Bank. World bank country and lending groups. 2023 Available: https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519-world-bank-country-and-lending-groups
- 19 Nicholls SG, McDonald S, McKenzie JE, et al. A review identified challenges distinguishing primary reports of randomized trials for meta-research: a proposal for improved reporting. J Clin Epidemiol 2022;145:121–5.
- 20 Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia Veritas Health Innovation. Available: https:// www.covidence.org/
- 21 Institute for Health Metrics and Evaluation (IHME). Global burden of disease 2019 cause and risk summary. Seattle, USA IHME, University of Washington; 2020. Available: https://www.healthdata. org/results/gbd_summaries/2019
- 22 Taljaard M, Goldstein CE, Giraudeau B, et al. Cluster over individual randomization: are study design choices appropriately justified? Review of a random sample of trials. *Clin Trials* 2020;17:253–63.
- 23 Lawrence DS, Hirsch LA. Decolonising global health: transnational research partnerships under the spotlight. *Int Health* 2020;12:518–23.
- 24 Hedt-Gauthier BL, Riviello R, Nkurunziza T, *et al.* Growing research in global surgery with an eye towards equity. *Br J Surg* 2019;106:e151–5.
- 25 United Nations. Millennium development goals and beyond 2015. 2015. Available: https://www.un.org/millenniumgoals
- 26 Institute for Health Metrics and Evaluation. Global burden of disease (gbd): key findings from gbd. 2019 Available: https://www.healthdata. org/research-analysis/gbd#:~:text=The%20Global%20Burden% 20of%20Disease,be%20improved%20and%20disparities% 20eliminated
- 27 United Nations. Sustainable development goals. 2023 Available: https://www.un.org/sustainabledevelopment/sustainabledevelopment-goals
- 28 Hemming K, Taljaard M, McKenzie JE, et al. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ 2018;363:k1614.

<u>ð</u>

Open access

- 29 Taljaard M, McRae AD, Weijer C, et al. Inadequate reporting of research ethics review and informed consent in cluster randomised trials: review of random sample of published trials. BMJ 2011;342:d2496.
- 30 Giraudeau B, Caille A, Le Gouge A, *et al*. Participant informed consent in cluster randomized trials: review. *PLoS One* 2012;7:e40436.
- 31 Odutayo A, Emdin CA, Hsiao AJ, *et al.* Association between trial registration and positive study findings: cross sectional study (Epidemiological Study of Randomized Trials-ESORT). *BMJ* 2017;356:j917.